混合ワクチン市場- 世界の産業規模、シェア、動向、機会、予測、製品タイプ別、適応疾患別、エンドユーザー別、地域別、競合別、2020～2030年

混合ワクチンの世界市場規模は2024年に196億9,000万米ドルで、2030年には341億米ドルに達し、CAGR9.56％で成長すると予測されています。

この大幅な市場拡大の背景には、予防医療に対する認識の高まりがあります。世界各国の政府や医療機関は、肺炎球菌感染症、インフルエンザ菌b型（Hib）、髄膜炎菌感染症などの感染症の蔓延を抑えるため、予防接種率の向上に注力しています。世界の医療支出の増加と、先進国と発展途上国の両方におけるワクチン接種プログラムの優先順位付けが、市場開拓に有利な環境を作り出しています。さらに、1つの製剤で複数の病原体を標的とするワクチンへの需要が、費用対効果を高めながら包括的な防御を提供する多価結合型ワクチンの開発に拍車をかけています。特に乳幼児や高齢者のような社会的弱者の間で、生命を脅かす病気を予防するワクチンの役割に対する認識が高まっていることも、市場拡大にさらに貢献しています。

市場促進要因

予防医療に対する意識の高まり

主要市場課題

高い製造コスト

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の混合ワクチン市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品タイプ別（一価結合ワクチン、多価結合ワクチン）
  • 適応疾患別（肺炎球菌、インフルエンザ、髄膜炎菌、腸チフス）
  • エンドユーザー別（病院クリニック、外来診療センター、その他）
  • 地域別
  • 企業別（2024年）
• 市場マップ
  • 製品タイプ別
  • 適応疾患別
  • エンドユーザー別
  • 地域別

第5章 アジア太平洋の混合ワクチン市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品タイプ別
  • 適応疾患別
  • エンドユーザー別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の混合ワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の混合ワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の混合ワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの混合ワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 製品上市
• 合併と買収

第12章 世界の混合ワクチン市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 産業内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Sanofi S.A
• Pfizer Inc.
• Merck & Co. Inc.
• GlaxoSmithKline plc
• Bharat BIoTech International Limited
• Serum Institute of India Pvt. Ltd
• Biological E. Limited
• Bavarian Nordic A/S
• CSL Limited
• Novartis AG

第15章 戦略的提言

第16章 調査会社について・免責事項

The Global Conjugate Vaccine Market was valued at USD 19.69 billion in 2024 and is projected to reach USD 34.10 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.56%. This significant market expansion is driven by the increasing recognition of preventive healthcare. Governments and healthcare organizations globally are focused on improving immunization coverage to reduce the prevalence of infectious diseases such as pneumococcal infections, Haemophilus influenzae type b (Hib), and meningococcal diseases. Rising global healthcare spending and the prioritization of vaccination programs in both developed and developing nations have created a favorable environment for market growth. Additionally, the demand for vaccines targeting multiple pathogens in a single formulation has spurred the development of multivalent conjugate vaccines, which offer comprehensive protection while enhancing cost-effectiveness. The growing awareness of vaccines' role in preventing life-threatening diseases, particularly among vulnerable populations like infants and the elderly, has further contributed to market expansion.

Key Market Drivers

Increasing Awareness of Preventive Healthcare

The growing awareness of preventive healthcare is a crucial factor driving the expansion of the Global Conjugate Vaccine Market. In recent years, there has been a notable shift from a curative to a preventive healthcare approach. This shift is supported by the understanding that preventing diseases through vaccination is more cost-effective and less burdensome on individuals and healthcare systems than treating illnesses after they occur.

Key Market Challenges

High Manufacturing Costs

The manufacturing complexity of conjugate vaccines arises from their unique composition. These vaccines combine a weak antigen with a potent one to generate a stronger immune response. Achieving this requires advanced biotechnological techniques and strict quality control throughout production. Additionally, rigorous regulatory requirements further contribute to the overall production cost. High manufacturing costs limit the accessibility of conjugate vaccines, especially in low- and middle-income countries, where budget constraints often hinder vaccine procurement and affordability. Even in developed countries with robust healthcare systems, the high cost of conjugate vaccines can pose challenges, potentially deterring healthcare providers and individuals from prioritizing these vaccines, despite their proven efficacy.

Key Market Players

• Sanofi S.A.
• Pfizer Inc.
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Bharat Biotech International Limited
• Serum Institute of India Pvt. Ltd
• Biological E. Limited
• Bavarian Nordic A/S
• CSL Limited
• Novartis AG

Report Scope

This report segments the Global Conjugate Vaccine Market by the following categories, along with detailed insights into industry trends:

By Product Type:

• Monovalent Conjugate Vaccines
• Multivalent Conjugate Vaccines

By Disease Indication:

• Pneumococcal
• Influenza
• Meningococcal
• Typhoid

By End-User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

By Region:

• North America:
• United States
• Canada
• Mexico
• Europe:
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific:
• China
• India
• Japan
• Australia
• South Korea
• South America:
• Brazil
• Argentina
• Colombia
• Middle East & Africa:
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

The competitive landscape includes detailed profiles of the major companies operating in the Global Conjugate Vaccine Market.

Available Customizations

TechSci Research offers customizations for the Global Conjugate Vaccine Market report to suit specific business needs. Customization options include:

• Detailed analysis and profiling of up to five additional market players.

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Conjugate Vaccine Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Product Type (Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine)
  • 4.2.2. By Disease Indication (Pneumococcal, Influenza, Meningococcal, Typhoid)
  • 4.2.3. By End-User (Hospitals & Clinics, Ambulatory care Centers, Others)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Product Type
  • 4.3.2. By Disease Indication
  • 4.3.3. By End-User
  • 4.3.4. By Region

5. Asia Pacific Conjugate Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type
  • 5.2.2. By Disease Indication
  • 5.2.3. By End-User
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Conjugate Vaccine Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Product Type
      • 5.3.1.2.2. By Disease Indication
      • 5.3.1.2.3. By End-User
  • 5.3.2. India Conjugate Vaccine Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Product Type
      • 5.3.2.2.2. By Disease Indication
      • 5.3.2.2.3. By End-User
  • 5.3.3. Australia Conjugate Vaccine Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Product Type
      • 5.3.3.2.2. By Disease Indication
      • 5.3.3.2.3. By End-User
  • 5.3.4. Japan Conjugate Vaccine Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Product Type
      • 5.3.4.2.2. By Disease Indication
      • 5.3.4.2.3. By End-User
  • 5.3.5. South Korea Conjugate Vaccine Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Product Type
      • 5.3.5.2.2. By Disease Indication
      • 5.3.5.2.3. By End-User

6. Europe Conjugate Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Disease Indication
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Conjugate Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Disease Indication
      • 6.3.1.2.3. By End-User
  • 6.3.2. Germany Conjugate Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Disease Indication
      • 6.3.2.2.3. By End-User
  • 6.3.3. Spain Conjugate Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Disease Indication
      • 6.3.3.2.3. By End-User
  • 6.3.4. Italy Conjugate Vaccine Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product Type
      • 6.3.4.2.2. By Disease Indication
      • 6.3.4.2.3. By End-User
  • 6.3.5. United Kingdom Conjugate Vaccine Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product Type
      • 6.3.5.2.2. By Disease Indication
      • 6.3.5.2.3. By End-User

7. North America Conjugate Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Disease Indication
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Conjugate Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Disease Indication
      • 7.3.1.2.3. By End-User
  • 7.3.2. Mexico Conjugate Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Disease Indication
      • 7.3.2.2.3. By End-User
  • 7.3.3. Canada Conjugate Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Disease Indication
      • 7.3.3.2.3. By End-User

8. South America Conjugate Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Disease Indication
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Conjugate Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Disease Indication
      • 8.3.1.2.3. By End-User
  • 8.3.2. Argentina Conjugate Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Disease Indication
      • 8.3.2.2.3. By End-User
  • 8.3.3. Colombia Conjugate Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Disease Indication
      • 8.3.3.2.3. By End-User

9. Middle East and Africa Conjugate Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Disease Indication
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Conjugate Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Disease Indication
      • 9.3.1.2.3. By End-User
  • 9.3.2. Saudi Arabia Conjugate Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Disease Indication
      • 9.3.2.2.3. By End-User
  • 9.3.3. UAE Conjugate Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Disease Indication
      • 9.3.3.2.3. By End-User
  • 9.3.4. Egypt Conjugate Vaccine Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Product Type
      • 9.3.4.2.2. By Disease Indication
      • 9.3.4.2.3. By End-User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Conjugate Vaccine Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Sanofi S.A
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Pfizer Inc.
• 14.3. Merck & Co. Inc.
• 14.4. GlaxoSmithKline plc
• 14.5. Bharat Biotech International Limited
• 14.6. Serum Institute of India Pvt. Ltd
• 14.7. Biological E. Limited
• 14.8. Bavarian Nordic A/S
• 14.9. CSL Limited
• 14.10. Novartis AG

15. Strategic Recommendations

16. About Us & Disclaimer